Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Overview

Lantern Pharma Inc. (NASDAQ: LTRN) conducted its earnings call for the third quarter of 2024 on November 7, 2024, at 4:30 PM ET. In attendance were key company leaders, including Panna Sharma (President and CEO), David Margrave (Chief Financial Officer), and Kishor Bhatia (Chief Scientific Officer).

The call began with an operator's announcement, welcoming participants and noting that the conversation would be recorded. Attendees were informed that they would have the opportunity to ask questions after the management's presentation. Furthermore, a replay of the conference call will be available on the corporate website shortly after the event.

Following the operator's introduction, Lantern Pharma released a press statement summarizing the company's financial performance and progress during the third quarter, which ended on September 30, 2024. The financial results and other pertinent details were provided in the release, accessible via the company's official website.

During the call, the management team reminded listeners that any forward-looking statements made are governed by the safe harbor provisions outlined in the Private Securities Litigation Reform Act of 1995. This means that while the company expressed its future expectations, several risks and uncertainties could lead actual results to differ significantly from those expectations.

Factors such as clinical trial outcomes and competition may impact results. The management emphasized that additional information about these risks is available in the company's annual report on Form 10-K for the year ending December 31, 2023, which is filed with the SEC and can be found on the established corporate website.

It is important to note that all forward-looking statements made during the earnings call are valid as of November 7, 2024. Lantern Pharma does not plan to update these statements following the call.

Earnings, Stocks, Pharma